Skip to content

Mannkind MNKD Accrued Issuance Costs Associated With Liability For Sale Of Future Royalties

Accrued Issuance Costs Associated With Liability For Sale Of Future Royalties at other companies

Rocket Lab USA, Inc. logo
Rocket Lab USA, Inc.RKLB
$0
Rumble, Inc. logo
Rumble, Inc.RUM
$220K
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$21M+50.0%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$1.25M
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$21M+50.0%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1.13B+42.1%

Other financials

Income statement

See full
Revenue$90.2M+15.1%
Gross profit$82.7M+10.8%
Operating income-$1.7M-107%
Net income-$16.6M-226%
EPS (diluted)-$0.05-225%

Balance sheet

See full
Cash & equivalents$52.8M+11.7%
Total debt$12.2M-9.4%
Total equity-$59.2M-1.0%
Total assets$744.4M+81.5%

Cash flow

See full
Operating cash flow-$5.4M+15.9%
CapEx$1.9M+470%
Free cash flow-$7.2M-8.0%

Valuation

See full
Market cap$1.19B+3.5%
Enterprise value$1.15B+3.0%
P/E228.5×
P/S3.3×-0.6×

Profitability

See full
Gross margin91.5%-2.6pp
Operating margin23.3%+3.1pp
Net margin9.3%
FCF margin13.8%

Returns & leverage

See full
Return on equity-8.8%
Debt / equity-0.2×
Current ratio1.9×-0.5×

Where this comes from

Reported directly by Mannkind in its filing.

Tagged under the XBRL concept mnkd:AccruedIssuanceCostsAssociatedWithLiabilityForSaleOfFutureRoyalties.

The official record: Mannkind’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mannkind's accrued issuance costs associated with liability for sale of future royalties.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mannkind's accrued issuance costs associated with liability for sale of future royalties?
Mannkind (MNKD) reported accrued issuance costs associated with liability for sale of future royalties of $81.25K in Q4 2023.
What does accrued issuance costs associated with liability for sale of future royalties mean?
This metric tracks the deferred or accrued expenses incurred during the structuring and execution of financing arrangements tied to the sale of future royalty streams. It represents the non-cash amortization or accumulation of costs associated with securing capital through revenue-based financing. Investors use this to understand the total cost of capital and the impact of financing-related liabilities on long-term cash flow obligations.